SCHEMBL4672571

SCHEMBL4672571

O=C(C=C(O)c1nc[nH]n1)c1cc(-c2ccccc2)on1

nearest known ligand 0.51

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.51
RAB9A P51151 6/20 0.48
NPC1 O15118 5/20 0.48
SMN1; SMN2 Q16637 4/20 0.48
KMT2A Q03164 3/20 0.48
MEN1 O00255 2/20 0.48
HPGD P15428 2/20 0.48
MAPT P10636 2/20 0.48
PKM P14618 1/20 0.48
HIF1A Q16665 2/20 0.43
FAAH O00519 3/20 0.43
S1PR1 P21453 1/20 0.43
PTPN1 P18031 1/20 0.43
MAPK1 P28482 1/20 0.42
STAT3 P40763 1/20 0.41
STAT1 P42224 1/20 0.41
LMNA P02545 1/20 0.41
SCD O00767 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4676970 0.81 NR4A2 (0.36) ALDH1A1RAB9ANPC1SMN1; SMN2KMT2A
SCHEMBL4675307 0.81 HPGD (0.46) ALDH1A1RAB9ANPC1SMN1; SMN2KMT2A
SCHEMBL4675863 0.79 HPGD (0.50) ALDH1A1RAB9ANPC1SMN1; SMN2KMT2A
SCHEMBL4676094 0.77 HDAC6 (0.43)
SCHEMBL4675492 0.77 CHRNA4 (0.41)
SCHEMBL4673892 0.76 HTR3E (0.35) RAB9ANPC1SMN1; SMN2MAPT
SCHEMBL4677542 0.75 RAB9A (0.44) ALDH1A1RAB9ANPC1SMN1; SMN2KMT2A
SCHEMBL4675259 0.75 KDM4E (0.35) ALDH1A1RAB9ANPC1SMN1; SMN2KMT2A
SCHEMBL4672704 0.75
SCHEMBL4675321 0.74 ALDH1A1 (0.39) ALDH1A1KMT2AMEN1MAPTPKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1142872-B1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO (JP) 2008-10-15 EP disclosed
US-7098201-B2 Heteroaromatic derivatives having an inhibitory activity against HIV integrase SHIONOGI & CO., LTD. (JP) 2006-08-29 US disclosed
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase FUJISHITA TOSHIO (JP) 2004-01-01 US disclosed
US-6645956-B1 1-(5-(4-fluorobenzyl)furan-2-yl)-3-hydroxy-3-(1H-1,2,4-triazol-3 -yl)-propenone; viricides; AIDS treatment SHIONOGI & CO., LTD. (JP) 2003-11-11 US disclosed
US-6620841-B1 Furan or benzofuran derivatives substituted with triazole; acquired immunodeficiency syndrome (AIDS) SHIONOGI & CO., LTD. (JP) 2003-09-16 US disclosed
CN-1335834-A Aromatic heterocyclic compounds having HIV integrase inhibitory activity SHIONOGI & CO (JP) 2002-02-13 CN disclosed
EP-1142872-A1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO., LTD. (JP) 2001-10-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase RCOR1, BCOR, CYP8B1 ALDH1A1 980/4885RAB9A 2021/4885NPC1 934/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.